<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83511">
  <stage>Registered</stage>
  <submitdate>15/01/2009</submitdate>
  <approvaldate>27/01/2009</approvaldate>
  <actrnumber>ACTRN12609000066280</actrnumber>
  <trial_identification>
    <studytitle>Investigation of Caspofungin Eye Drops for the Treatment of Fungal Eye Infections</studytitle>
    <scientifictitle>Ocular Penetration of Caspofungin Eye Drops in the Treatment of Fungal Keratitis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Fungal Keratitis</healthcondition>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>One drop of 0.5% Caspofungin eye drops will be administered hourly into the eye that will be operated on (commencing 4 hours before participant's elective surgery).</interventions>
    <comparator>No</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Penetration of Caspofungin into the aqueous humour of the eye. The concentration of caspofungin in the eyes will be measured using high performance liquid chromatography (HPLC) or liquid-chromatography-mass-spectrometry (LC-MS).</outcome>
      <timepoint>An hour after the last dose given. One drop hourly (commencing 4 hours before participant's elective surgery).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Adequate concentration of caspofungin achieved in the aqueous humour of the eye to treat fungal keratitis. The concentration of caspofungin in the eyes will be measured using high performance liquid chromatography (HPLC) or liquid-chromatography-mass-spectrometry (LC-MS).</outcome>
      <timepoint>An hour after the last dose given. One drop hourly (commencing 4 hours before participant's elective surgery).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients attending for elective eye surgery (eg. cataract surgery)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Participants in whom the use of caspofungin is contraindicated (eg. pregnancy, hypersensitivity to caspofungin or its formulation, risk of clinically significant drug interactions or as per caspofungin's product information guide)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/04/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Monash</primarysponsorname>
    <primarysponsoraddress>381, Royal Parade, Parkville, VIC 3052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Contributing to Australian Scholarship &amp; Sciences (CASS) Foundation</fundingname>
      <fundingaddress>Level 2, 111 Collins Street, Melbourne, Victoria 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>The Royal Victorian Eye &amp; Ear Hospital (RVEEH)</othercollaboratorname>
      <othercollaboratoraddress>32, Gisborne Street, East Melbourne, VIC 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This proposed study is intended to investigate if the antifungal drug, caspofungin, when applied as an eye drop is able to penetrate into the human eyes. The use of caspofungin as an eye drops in human has never been reported. Caspofungin eye drops are anticipated to safely penetrate into the human eyes when applied as eye drops and to achieve adequate concentrations to treat fungal eye infections.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>9/02/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>2/02/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr David CM Kong</name>
      <address>Department of Pharmacy Practice
Faculty of Pharmacy and Pharmaceutical Sciences
381, Royal Parade, Parkville, VIC 3052</address>
      <phone>+61 3 9903 9035</phone>
      <fax>+61 3 9903 9629</fax>
      <email>david.kong@pharm.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr David CM Kong</name>
      <address>Department of Pharmacy Practice
Faculty of Pharmacy and Pharmaceutical Sciences
381, Royal Parade, Parkville, VIC 3052</address>
      <phone>+61 3 9903 9035</phone>
      <fax>+61 3 9903 9629</fax>
      <email>david.kong@pharm.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr David CM Kong</name>
      <address>Department of Pharmacy Practice
Faculty of Pharmacy and Pharmaceutical Sciences
381, Royal Parade, Parkville, VIC 3052</address>
      <phone>+61 3 9903 9035</phone>
      <fax>+61 3 9903 9629</fax>
      <email>david.kong@pharm.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>